About Curapath - A European CDMO for Non-Viral Drug Delivery
Curapath is a European Contract Development and Manufacturing Organization (CDMO) specialized in polymer- and lipid-based non-viral drug delivery systems and their components. This includes the development and manufacturing of polymer and lipid excipients, lipid nanoparticles (LNPs), polymer nanoparticles (PNPs), and advanced drug conjugation strategies. We support regulated biotech, pharmaceutical, and medical device programs from early development through GMP and commercial manufacturing.
Curapath offers a combination of off-the-shelf R&D and GMP-grade materials, as well as custom development services, enabling our partners to progress efficiently from early feasibility to scalable and regulatory-ready manufacturing. Our solutions include PEG alternatives, active targeting strategies for lipid nanoparticles (LNPs), and tunable transfection reagents, all designed with a strong focus on manufacturability, reproducibility, and long-term regulatory compliance, supporting both clinical and commercial supply of advanced delivery technologies.
Quick Facts
- Type of company:European Contract Development and Manufacturing Organization (CDMO)
- Specialization:Non-viral drug delivery systems
- Core technologies: Polymer and Lipid based delivery systems (LNPs,PNP,Polymer and Lipid excipients)
- Capabliities : R&D, GMP manufacturing, commercial supply
- Regulatory status: GMP certified, EMA & FDA (2026) inspected
- Markets adressed:Oncology, cell and gene therapy, DNA and mRNA vaccines, medical devices, in vivo CAR-T programs and trasfection reagents
Curapath’s
Core Values
We care
We develop our people.
We are customer centric.
We respect our suppliers.
Always with patients in mind.
We never give up
We think out of the box,
we design, test,
adapt and continuously improve.
We welcome problems
We strive for scientific innovation
and operational excellence to
create value in the market.
Why Choose Us
At Curapath, our top priority is delivering exceptional customer satisfaction. To maintain and enhance our service, we regularly conduct satisfaction surveys among our valued clients. Our current Net Promoter Score (NPS) stands at an astonishing 61, reflecting the high-level satisfaction from our customers and Curapath commitment in our customer-centric approach. We remain devoted to continuously improving this score through dedicated efforts and a focus on excellence.
Your Tailored Drug Delivery Solution
During an initial interaction, our technically proficient Business Development team will conduct a preliminary assessment of your needs. The primary objectives are to gain an understanding of your current development stage and the specific characteristics of your product at a high level, as well as to introduce Curapath’s capabilities.
A Project Manager will be appointed to support you and start building a project framework, by establishing requirements, planning timelines and defining deliverables. You will receive a preliminary time & budget proposal within 48 hours, once the project scope has been agreed.
Once the project gets started, your Project Manager will be your primary contact throughout the lifecycle of your project, providing progress reporting and walking you through the activities.
We prioritize quality standards and work efficiency in every project, ensuring that we not only meet but exceed our clients’ expectations. That’s why our average On-Time In-Full (OTIF) performance exceeds 93%, reflecting our unwavering commitment to customer satisfaction and excellence. This dedication to delivering projects on time and in full underscores our promise to provide reliable and high-quality service, reinforcing our position as a trusted partner in your success.
Project Management Support Every Step of the Way
Once your project gets started, a PMI-certified* Project Manager will actively participate from the very early interaction and accompany you throughout the entire project lifecycle, ensuing product quality compliance and on-time delivery.
Your appointed Project Manager will:
- Design and plan a customized project based on required milestones, deliverables, and budget.
- Report project progress and key data on the agreed frequency with transparency and honesty.
- Provide continuous technical advice and engage subject matter matter experts to the discussions when needed.
- Keep budgets on track and identify cost reductions wherever possible.
- Be flexible and adaptive to changes in project scope, requirements, or external factors that may impact the project.
- Apply agile methodologies, when possible, for continuous project improvement.
- Monitor and adjust schedules as necessary to ensure project milestones are met.
Frequently Asked Questions
What is Curapath
Curapath is a European Contract Development and Manufacturing Organization (CDMO) specialized in non-viral drug delivery systems. We support biotech and pharmaceutical companies from early development through GMP-ready and commercial manufacturing, combining proprietary delivery components, in-house technologies, and deep expertise in complex formulation and CMC development.
What type of drug delivery systems does Curapath specialize in?
Curapath specializes in non-viral drug delivery systems, including lipid nanoparticles (LNPs), targeted LNPs (tLNPs), polymer-based delivery platforms, and proprietary delivery components such as PEG alternatives. Curapath offers both off-the-shelf R&D and GMP-grade polymers and lipids, as well as custom, project-specific delivery solutions tailored to the molecule, indication, and development stage, with a strong focus on manufacturability, scalability, and regulatory readiness.
Is Curapath GMP certified and inspected by regulatory agencies
Yes. Curapath operates under GMP standards and is GMP certified. Our facilities have been inspected by both the European Medicines Agency and the U.S. Food and Drug Administration (during 2026), supporting programs intended for European and U.S. clinical and commercial supply.
Does Curapath supply products at commercial scale?
Yes. Curapath currently supplies products at commercial scale and supports more than 15 clinical trials, demonstrating its ability to deliver robust, reproducible manufacturing beyond clinical development. Curapath’s commercial supply includes polymer-based excipients, such as a PEG-copolymer and an additional polymeric excipient, manufactured under GMP conditions for regulated pharmaceutical applications.
Does Curapath develop PEG alternatives and delivery components?
Yes. Curapath develops and manufactures advanced delivery components, including PEG alternatives designed to address limitations associated with PEGylation, such as immunogenicity and long-term safety concerns.
This alternatives can be used for both LNP formulations and Protein conjugation
Who does Curapath work with?
Curapath works with biotech startups, scale-ups, and pharmaceutical companies developing advanced therapies that require specialized expertise in non-viral drug delivery and complex manufacturing processes.
Does Curapath offer solutions for specific markets or applications?
Yes. Curapath supports regulated pharmaceutical and medical device applications, developing delivery systems, components, and functional polymer materials tailored to the specific technical, regulatory, and manufacturing requirements of each market.
Curapath’s solutions address a range of advanced therapeutic areas, including oncology, cell and gene therapy, DNA and mRNA vaccines, medical devices, and programs developing in vivo CAR-T therapies.
Meet Our Team
Philippe is the Chief Executive Officer of Curapath. He brings over 25 years of experience in chemical & pharmaceutical industry, with a specific focus on active pharmaceutical ingredient market (CDMO & Generics) and drug delivery solutions from R&D to commercial. Philippe has an extensive track record not only with regards to business development and the creation of trustful partnerships in Europe / US / Japan but also in process development, industrialization, and continuous improvement. Before joining Curapath, Philippe worked for 3 international companies with extensive development and manufacturing capabilities for pharmaceutical markets – Rhodia (now Solvay), Sanofi and Seqens – where he engaged and led global teams towards ambitious roadmaps and through challenging projects. For instance, Philippe was instrumental to secure the complex supply chain of oligosaccharides obtained by total synthesis and developed as animal free alternatives to heparinoids to treat thrombosis, to accelerate the installation of new manufacturing solutions for the hypertension market in Japan facing Fukushima crisis, to create new capacities for viral vectors manufacturing to face growing patients’ needs, and to establish the appropriate industrial scheme for supporting the worldwide commercial launch of a breakthrough therapy for amyotrophic lateral sclerosis. Philippe received two awards from Sanofi for his entrepreneurship and partnership achievements. He graduated from the Engineering School of Physics and Chemistry of Bordeaux (now ENSMAC), and obtained his PhD at University of Bordeaux, funded by EDF and Rhône-Poulenc/Rhodia, for which he was awarded best PhD thesis of French Chemical Society (SFC).
Vicent is the Chief Technology Officer of Curapath. He brings more than 15 years of experience in the field of nanomaterials and drug delivery systems in both industry and academic settings, having co-authored more than 40 publications (including articles, book chapters and patents) in the field, and been awarded several grants as co-PI. Before his time at Curapath, he was Research Collaborator at Centro de Investigación Príncipe Felipe (CIPF). Vicent is an expert in polypeptide-based systems, soft materials, supramolecular chemistry, and physico-chemical characterization with a special focus on CMC development of drug nanomedicines and their regulatory aspects. Vicent obtained his Ph.D. degree in Chemistry and Material Science, funded by Procter & Gamble, from Universidad Jaume I de Castelló in 2012. After a post-doctoral period of 3 years at Polymer Therapeutics Laboratory, headed by Dr. Maria J. Vicent, Vicent joined PTS as a researcher awardee of Torres Quevedo Spanish Ministry Program. He also participated in MIT Sloan School of Management’s Entrepreneurship Development Program.
Carles is Head of Business Development at Curapath. He holds a PhD in Organic Chemistry and an MSc in Applied and Pharmacological Chemistry, with over +10 years of experience in the nanomedicine field. Since joining Curapath as a Project Manager in 2018, He has been a key player in expanding the company’s capabilities in non-viral delivery systems. With +15 high-impact publications and +5 patents, he brings both scientific innovation and strategic foresight to the team delivering innovative solutions aligned with both market demands and Curapath’s strategic vision. His leadership has been crucial in managing programs from early development through clinical stages, offering tailored solutions that address the specific needs of both early adopters and late-stage customers. By providing innovative products and services, he ensured a smooth transition from concept to market, helping customers at advanced stages maximize value and meet their clinical and commercialization goals. In his current role, he heads Curapath’s Sales and Business Development team, driving business growth by capturing new opportunities and guiding the company’s strategic initiatives to meet the evolving demands of late-stage customers.
José María is the Supply Chain & Procurement Director at Curapath. He brings more than 15 years of international experience in operations, supply chain management, and industrial project execution within the pharmaceutical and technology sectors. Before joining Curapath, he held several leadership roles at Nice Tech, including Head of Operations and Head of Supply Chain, managing facilities across the Philippines, Morocco, Mexico, and Spain. Earlier in his career, he led large-scale industrial plant projects and served as Project Manager at AKO and later at SURIS.
José María holds an Executive MBA from ESADE Business School and has completed executive education at HEC Paris. His combined expertise in engineering, procurement, and executive leadership enables him to drive supply chain innovation and support Curapath’s mission to deliver cutting-edge non-viral delivery technologies.
Ángeles is Finance Director at Curapath. She holds a Bachelor’s Degree in Economic and Business Sciences from the University of Valencia and brings more than 30 years of experience as Head of Finance in national and international companies across the technology, automotive, automation, and import-export sectors, as well as in financial consulting. Since joining Curapath in 2021, she has been instrumental in developing the Finance Department, implementing new financial and accounting processes and procedures to strengthen the company’s structure.
With solid expertise in financial reporting, forecasting, treasury management, taxation, auditing, and management control, Ángeles combines strong analytical skills with a collaborative approach. Her strategic and results-driven mindset ensures sound financial management, enabling Curapath to sustain growth while meeting both operational and long-term business objectives.
Jose is Operations Director at Curapath. Jose brings over 15 years of experience in the pharmaceutical field, working in Operations and Quality. He is a pharmacist with a Master’s degree in Pharmaceutical Industry and a Master’s in Biomedical Biotechnology. Before joining Curapath, he spent over five years as an inspector for the Spanish Health Authorities assessing the GMP compliance of commercial Drug Substances and Drug Products manufacturers. Since he joined Curapath, he has led the creation and implementation of the quality system from scratch, organized the manufacturing departments according to GMP standards, and led the construction of Curapath’s GMP facilities for both Drug Substances and Sterile Drug Products.
Sergio is the Chemistry, Manufacturing and Controls Director at Curapath. He is a chemist by training and holds a Ph.D. in organic chemistry. Sergio has over 15 years of experience in developing, validating, and transferring processes and analytical methods for new active ingredients(API) and drug products. In addition, he has developed his skills in producing novel radiopharmaceuticals and polymer-based products for clinical trials and in the methods to control the quality of these products. Sergio joined Curapath in 2016 as Quality Control Manager and was instrumental in the creation of Curapath’s Quality Control department and the building Curapath’s overall Quality Systems. Sergio supports our client’s therapeutic programs from early feasibility, overseeing clinical GMP manufacturing through process validation and commercial manufacturing.
Aroa is a chemist by training and holds a PhD in Biochemistry and Biotechnology. She brings more than 10 years of experience in drug delivery and polymer science. She joined Curapath in 2021 as R&D manager. Aroa did her PhD at the CIPF in Valencia at the Polymer Therapeutics Lab self-funded with a fellowship from the national scheme. Then, she moved to the Molecular Bionics lab in UCL London for a postdoctoral experience, with first the competitive Newton International fellowship from the Royal Society of UK, and later with a Marie Curie fellowship from the European Commission. Her scientific background has provided her with vast experience in project management, supervising skills and successful grants applications. She counts with more than 30 publications including patents and research monographs. Aroa joined Curapath as a research awardee Torres Quevedo Spanish Ministry Program and since then, she has provided structure to the R&D Department to guarantee the continuous innovation of the company projects.
Juan José is the Head of Project Management at Curapath. He is a trained chemist with a MSc. in Supramolecular Chemistry and a Ph.D. in Biochemistry and Biomedicine. He possesses +10 years in the development of nanomedicines and novel polymer-based drug delivery systems for multiple biomedical applications, including their physicochemical characterization and preclinical evaluation. He has authored +10 high impact publications in the field.
Juan José joined Curapath as Project Manager in early 2019 through a Torres Quevedo grant. Since then, he has accumulated an extensive experience in the management of complex projects in different stages of the clinical pathway.
As Head of Project Management, Juan José leads an interdisciplinary team of highly skilled Project Managers whose mission is to coordinate the operational internal teams to ensure efficient projects execution, while supporting business growth by efficient client’s relationship management. Additionally, Juan José manages several projects undergoing IND/IMPD applications and early clinical trials.